All In Biotech

Free tool

FAERS Monitor: Trutakna

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761486 or its brand name (Trutakna, Atacicept-Vymj). Reports on generic versions are filed under their own applications.

Reports

8

Serious

8

100% of reports

Hospitalization

0

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blood immunoglobulin g decreased3
  • bedridden2
  • burning sensation2
  • diarrhoea2
  • illness2
  • inflammation2
  • influenza like illness2
  • laboratory test abnormal2
  • nausea2
  • pain2
  • petechiae2
  • rash2
  • renal impairment2
  • scar2
  • steroid withdrawal syndrome2

Reports by year received

View as table
YearReports
20121
20161
20193
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,151 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
steroid withdrawal syndrome25160.31551.45,791
blood immunoglobulin g decreasedSignal33187.41301.86,628
petechiae2503.7151.7564
bedridden2400.1120.5447
scar2307.292.5343
laboratory test abnormal2178.253.7198
inflammation2101.930.7112
burning sensation275.022.682
influenza like illness263.919.269
renal impairment262.618.868
illness251.015.455
rash212.13.611
pain28.62.67
diarrhoea28.12.57
nausea26.62.05

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.